Med-tech happenings, including deals and partnerships, grants, preclinical data and other news in brief: Alira Health, Bausch & Lomb, Bausch Health, Caredx, Cros NT, Dariohealth, Delcath Systems, Icad, Lochan, Psyinnovations, Transplant Hero, Ubiquitome, Weavr Health.

Regulatory snapshots, including global submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Abbott, Alpha Tau Medical, Angiodynamics, Elute, Eyeyon Medical, Glaukos, Mimedx, Roche.

Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Abbive, Alessa, Amicus, Amryt, Ascletis, Bavarian Nordic, Bergenbio, Bluebird, Cantargia, Crestone, Cullinan, Iaso, Incyte, Kiniksa, Liminal, Moderna, Neoimmunetech, Novo Nordisk, Spinogenix Takeda, VBI.

Biopharma happenings, including deals and partnerships, grants, preclinical data and other news in brief: Annovis, Daewoong, GC, Humacyte, ICM, Immutep, Indivior, Inovio, Karolinska Institut, Mcurex, Neurogastrx, Olix, Onk, Onward, PBG, Samyang, Revive, Sanofi, Seagen, Sorrento, Springworks, Supriva, Translate.

Clinical updates, including trial initiations, enrollment status and data readouts and publications: Addex, Aivita, Alnylam, Ardelyx, Arena, Astrazeneca, Atara, Aurinia, Azurrx, Beyondspring, Bio-Thera, Cardiff, Chemocentryx, Citius, Crestone, Glenmark, In8bio, Inflarx, Innovent, Kazia, Mei, Neurana, Novartis, Noxxon, Oramed, Outlook, Oxurion, Redhill, Takeda, Vaccinex.

Med-tech happenings, including deals and partnerships, grants, preclinical data and other news in brief: Allelica, Bruker, Cardiac Insights, Elekta, Entegris, Heliodx, Icecure Medical, Inteneural Networks, Ktrfios Importacao E Exportacao, Neovasc, Philips, Rushnet, Suralign Holdings, Thermo Fisher Scientific.

Regulatory snapshots, including global submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Avacta Group, Medtronic, Opgen, Orasure Technologies.

Sinovac Biotech Ltd.'s inactivated COVID-19 vaccine, Coronavac, has been approved by Chinese regulators for emergency use in children aged between 3 and 17, the company’s CEO Yin Weidong told Chinese state media on June 4. Sinovac briefly unveiled phase I/II data in the age group back in April. Chinese state media, China Central Television, said it confirmed the news with an expert from China’s State Council, though an official announcement has yet to be made. Sinovac did not immediately respond to BioWorld’s query to confirm the news.

Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Alexion.